Robert W. Baird Upgrades Sensei Biotherapeutics (NASDAQ:FTH) to Strong-Buy

Sensei Biotherapeutics (NASDAQ:FTH) was upgraded by analysts at Robert W. Baird to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

A number of other brokerages have also weighed in on FTH. BTIG Research raised Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, June 11th. HC Wainwright initiated coverage on Sensei Biotherapeutics in a report on Monday, June 22nd. They set a “buy” rating and a $60.00 target price for the company. Finally, Weiss Ratings began coverage on Sensei Biotherapeutics in a research report on Wednesday, June 17th. They issued a “sell (d-)” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $58.50.

Sensei Biotherapeutics Stock Down 7.3%

Shares of FTH opened at $22.87 on Thursday. Sensei Biotherapeutics has a one year low of $6.32 and a one year high of $36.76. The stock has a market cap of $30.69 million, a price-to-earnings ratio of -0.16 and a beta of -0.25.

Insider Buying and Selling at Sensei Biotherapeutics

In related news, CEO Anand Kiran Parikh acquired 2,806 shares of Sensei Biotherapeutics stock in a transaction on Monday, June 22nd. The stock was acquired at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the purchase, the chief executive officer owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. This represents a 0.37% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Brian C. Stephenson acquired 6,250 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was bought at an average cost of $24.95 per share, with a total value of $155,937.50. Following the acquisition, the chief financial officer owned 33,054 shares in the company, valued at approximately $824,697.30. This trade represents a 23.32% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders acquired 35,860 shares of company stock worth $862,703. 7.00% of the stock is owned by corporate insiders.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.